Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174310 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
A Phase 3 study of Parkinson's Disease, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT07174310: Recruiting Phase 3 study of Parkinson's Disease, sponsored by Hoffmann-La Roche.
NCT07174310 is a Phase 3 study of Parkinson's Disease that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 900 participants, above the 630-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07174310, a Phase 3 study of Parkinson's Disease, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prasinezumab
Study Locations (20)
Florida
- JEM Research LLC - Atlantis
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- K2 - Villages - Lady Lake
- K2 Medical Research-Maitland - Maitland
- Charter Research - Winter Park/Orlando - Orlando
California
- Neurology Center of North Orange County - Fullerton
- Keck School of Medicine of USC - Los Angeles
- Profound Research LLC at The Neurology Center of Southern California - Pasadena
- UCSF Weill Institute for Neurosciences - San Francisco
New York
- Dent Neurological Institute - Amherst
- Weill Cornell Medical College - New York
Colorado
- Rocky Mountain Movement Disorders - Englewood
Connecticut
- Institute for Neurodegenerative Disorders - New Haven
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Michigan
- Quest Research Institute - Farmington Hills
Nevada
- Renown Health - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 3 |
What NCT07174310 shows while recruiting
NCT07174310 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 630-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07174310 names 20 study sites across 12 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT07174310 about?
NCT07174310 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease". The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
What is the current status of trial NCT07174310?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2025-11-24. Estimated completion is 2031-06-30.
What conditions does trial NCT07174310 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT07174310?
The interventions under investigation include: Placebo (DRUG), Prasinezumab (DRUG).
Who is sponsoring clinical trial NCT07174310?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174310 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07174310's enrollment target sits among peer trials
900 10th of 158 higher than 149 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ACTIVE NOT RECRUITING · Phase 3
-
Deep Brain Stimulation for Parkinson's Disease Trial
COMPLETED · Phase 3
-
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
COMPLETED · Phase 3
-
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI